source
- Capricor's Duchenne therapy is rejected again, as FDA cites significant issues with trialCapricor Therapeutics’ deramiocel cell therapy was rejected for a second time by the FDA on Friday, despite the company's pivot to a narrower indication within Duchenne muscular dystrophy. In aEndpoints · 1h ago↗ source
- Revolution Medicines reports strong data for KRAS-targeted pancreatic cancer drug amid rising competitionRevolution Medicines presented encouraging results for its KRAS‑targeted therapy aimed at pancreatic cancer at a recent industry meeting. The company highlighted the potency of the drug in preclini…